UBS Group Cuts 10x Genomics (NASDAQ:TXG) Price Target to $14.00

10x Genomics (NASDAQ:TXG – Free Report) had its target price reduced by UBS Group from $20.00 to $14.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a neutral rating on the stock. Several other analysts also recently weighed in on the company. Citigroup cut their target price on 10x Genomics […]

Leave a Reply

Your email address will not be published.

Previous post Cytokinetics (NASDAQ:CYTK) Upgraded by Morgan Stanley to Overweight Rating
Next post Editorial: Musk bid for OpenAI exposes hypocrisy of business model